Navigation Links
Vanda Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 7, 2013
Date:10/21/2013

WASHINGTON, Oct. 21, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the third quarter of 2013 on Thursday, November 7, 2013, before the market opens.

The Company will host a conference call at 10:00 AM ET on Thursday, November 7, 2013, during which Vanda management will discuss the financial results.  To participate in the conference call, please dial 1-888-895-5271 (domestic) or 1-847-619-6547 (international) and use passcode 35919679.

The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com.  Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, November 7, 2013, beginning at 12:00 PM ET and will be accessible until Thursday, November 14, 2013, at 5:00 PM ET.  The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers.  The passcode number is 35919679.

ABOUT VANDA PHARMACEUTICALS INC.:    
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.  

Investor Contact:   
Chad Rubin
Vice President
The Trout Group
(646) 378-2947
crubin@tro
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock
2. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
3. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
4. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
5. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
6. Vanda Pharmaceuticals, Inc. Sued by Investor
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
9. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
10. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
11. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ) today ... quarter of 2013 on Monday, February 3, 2014. A press ... close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... the operating highlights and financial results for the fourth quarter ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... issued today a shareholders, letter discussing the results of its fiscal ... Dear Imagenetix shareholder - Following ... we commence the new fiscal year, I would like to address ...   Over the past few years our primary strategy ...
... July 12, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... 1 clinical trial of APD811, an orally bioavailable agonist ... treatment of pulmonary arterial hypertension, or PAH. ... tolerability and pharmacokinetics of 0.03 mg, 0.05 mg, 0.1 ...
Cached Medicine Technology:Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 2Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension 4
(Date:4/24/2014)... WINSTON-SALEM, N.C. April 24, 2014 ,Take me ... of apple slices and kale chips. The more likely ... of Crackerjacks. , Unfortunately for children who play ... may be contributing to weight problems, according to researchers ... in the current online edition of Childhood Obesity ...
(Date:4/24/2014)... Center for BrainHealth will bring together national experts ... challenges at its inaugural Brain Health Summit, titled ... speakers will include Dr. Sandra Bond Chapman, founder ... U.S. Senator Chuck Grassley (R-IA), U.S. Representative Chaka ... for Policy and Early Learning, U.S. Department of ...
(Date:4/24/2014)... to be boring and irrelevant, could offer an alternative ... Researcher Dr Milena Furtado, and her team from the ... the heart cell fibroblast is a close relative to ... heart. , In research published today in Circulation ... are unique cells due to their genetic program, and ...
(Date:4/24/2014)... epidemic of prescription opioid overdose deaths was outlined yesterday ... by leaders of agencies in the U.S. Department of ... health care providers to expand their use of medications ... describes a number of misperceptions that have limited access ... how medications can be used in combination with behavior ...
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Boring cells could hold the key to heart disease 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Study: Altruistic adolescents less likely to become depressed 2
... day, March 20, we celebrate head injury awareness day. This ... annual incidences of head injuries. Every day, 500,000 people are ... or the other and it is the sixth most common cause ... globe in the U.S, every 15 seconds, a person suffers a ...
... this time. Beer, wine and spirits bottles will now be ... trying to conceive. The decision follows fears over ... officials warn of subsequent risks such as fetal alcohol syndrome ... have been protests from the liquor lobby that say that ...
... ‘disgusting’ reports that reveal millions of pounds being collected in ... , The figures disclosed under the Freedom of ... pounds being made during 2005/2006,some trusts raised more than one ... charges" on the weak and vulnerable. The top ...
... has undergone liver transplant is convalescing well. This was ... Russell Britz the Head of the Transplant Unit at ... minister needed this liver transplant very urgently and that ... operation done. ,The Measure for End Stage ...
... provide quality care to patients. In a recent report, ... scan results never reach the doctors table. The report ... ,Worse still, the results reach Doctors via informal ... a tacit agreement between the department and the Doctor ...
... persistent asthma have a level of control that is ... the journal of Ambulatory Pediatrics. ,"That leaves almost ... to," said the study's lead author, Jill Halterman, M.D., ... at Strong. "They may be experiencing unnecessary symptoms, missed ...
Cached Medicine News:Health News:Head Injury Awareness Day 2Health News:Head Injury Awareness Day 3Health News:Babies and Drinks Don’t Mi 2Health News:Easy Money-NHS Trusts Make Millions from Parking Fees 2Health News:Asthmatic Children Still Not Breathing Easier, Study Says 2
Large deep curve....
3 mm electrode Inserts - monopolar foot control connection....
... is an Auto Refractor/Keratometer with ... refinement. Electronic elevation, automatic alignment, ... accuracy and all the other ... Marco Automatic Refractors/Keratometer famous, make ...
Sterile perfluorocarbon for intraocular Application....
Medicine Products: